Genpact (G) Competitors $45.69 -0.44 (-0.95%) Closing price 03:57 PM EasternExtended Trading$45.69 0.00 (0.00%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock G vs. CCRN, BR, GPN, JKHY, EXLS, WEX, EEFT, PAY, MMS, and WUShould you be buying Genpact stock or one of its competitors? The main competitors of Genpact include Cross Country Healthcare (CCRN), Broadridge Financial Solutions (BR), Global Payments (GPN), Jack Henry & Associates (JKHY), ExlService (EXLS), WEX (WEX), Euronet Worldwide (EEFT), Paymentus (PAY), Maximus (MMS), and Western Union (WU). Genpact vs. Its Competitors Cross Country Healthcare Broadridge Financial Solutions Global Payments Jack Henry & Associates ExlService WEX Euronet Worldwide Paymentus Maximus Western Union Cross Country Healthcare (NASDAQ:CCRN) and Genpact (NYSE:G) are related companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings. Is CCRN or G more profitable? Genpact has a net margin of 10.88% compared to Cross Country Healthcare's net margin of -1.41%. Genpact's return on equity of 22.35% beat Cross Country Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Cross Country Healthcare-1.41% 2.56% 1.84% Genpact 10.88%22.35%10.50% Which has more volatility & risk, CCRN or G? Cross Country Healthcare has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Genpact has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Does the media favor CCRN or G? In the previous week, Genpact had 7 more articles in the media than Cross Country Healthcare. MarketBeat recorded 10 mentions for Genpact and 3 mentions for Cross Country Healthcare. Genpact's average media sentiment score of 0.75 beat Cross Country Healthcare's score of 0.43 indicating that Genpact is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cross Country Healthcare 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genpact 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in CCRN or G? 96.0% of Cross Country Healthcare shares are held by institutional investors. Comparatively, 96.0% of Genpact shares are held by institutional investors. 4.9% of Cross Country Healthcare shares are held by insiders. Comparatively, 3.1% of Genpact shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, CCRN or G? Genpact has higher revenue and earnings than Cross Country Healthcare. Cross Country Healthcare is trading at a lower price-to-earnings ratio than Genpact, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCross Country Healthcare$1.34B0.31-$14.56M-$0.53-23.68Genpact$4.77B1.68$513.67M$2.9315.59 Do analysts recommend CCRN or G? Cross Country Healthcare presently has a consensus price target of $17.93, suggesting a potential upside of 42.87%. Genpact has a consensus price target of $50.14, suggesting a potential upside of 9.75%. Given Cross Country Healthcare's higher probable upside, analysts plainly believe Cross Country Healthcare is more favorable than Genpact.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cross Country Healthcare 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Genpact 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43 SummaryGenpact beats Cross Country Healthcare on 13 of the 15 factors compared between the two stocks. Get Genpact News Delivered to You Automatically Sign up to receive the latest news and ratings for G and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding G and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart G vs. The Competition Export to ExcelMetricGenpactIT Services IndustryComputer SectorNYSE ExchangeMarket Cap$8.07B$17.62B$27.57B$20.51BDividend Yield1.47%1.48%3.12%3.73%P/E Ratio15.5940.4637.3427.90Price / Sales1.6812.741,937.0840.84Price / Cash12.8226.0038.4422.25Price / Book3.375.137.274.59Net Income$513.67M$434.10M$764.25M$982.91M7 Day Performance1.56%0.18%1.73%0.74%1 Month Performance5.78%-0.33%5.26%3.94%1 Year Performance47.63%29.83%52,407.62%14.82% Genpact Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GGenpact3.3728 of 5 stars$45.69-1.0%$50.14+9.7%+47.3%$8.07B$4.77B15.59140,000CCRNCross Country Healthcare4.0848 of 5 stars$13.05+2.0%$17.93+37.4%-6.6%$427.78M$1.34B-24.628,205BRBroadridge Financial Solutions4.2431 of 5 stars$242.85+1.4%$250.83+3.3%+17.7%$28.53B$6.51B36.5214,300Positive NewsGPNGlobal Payments4.9869 of 5 stars$80.23+1.9%$110.91+38.2%-15.6%$19.57B$10.10B12.9425,000Positive NewsAnalyst ForecastJKHYJack Henry & Associates4.4223 of 5 stars$180.17+1.0%$185.11+2.7%+9.7%$13.12B$2.22B30.697,170Positive NewsEXLSExlService4.6267 of 5 stars$43.79-0.1%$51.50+17.6%+41.3%$7.12B$1.90B33.1759,500Positive NewsHigh Trading VolumeWEXWEX4.1545 of 5 stars$147.02+0.1%$176.90+20.3%-14.6%$5.03B$2.63B18.956,500EEFTEuronet Worldwide4.3388 of 5 stars$101.38-0.5%$125.57+23.9%+4.4%$4.38B$3.99B15.0210,600News CoveragePositive NewsPAYPaymentus4.1548 of 5 stars$32.77+1.6%$36.80+12.3%+59.0%$4.10B$871.74M84.031,307High Trading VolumeMMSMaximus3.8116 of 5 stars$70.38+0.6%$90.00+27.9%-16.1%$3.97B$5.31B13.9941,100Dividend AnnouncementWUWestern Union4.3367 of 5 stars$8.44+0.8%$10.78+27.7%-29.2%$2.79B$4.21B3.159,100 Related Companies and Tools Related Companies Cross Country Healthcare Competitors Broadridge Financial Solutions Competitors Global Payments Competitors Jack Henry & Associates Competitors ExlService Competitors WEX Competitors Euronet Worldwide Competitors Paymentus Competitors Maximus Competitors Western Union Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:G) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genpact Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Genpact With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
